Want to see HK:6127 full AI Analyst Report?
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$15.13 - HK$32.58
Previous CloseN/A
Volume546.17K
Average Volume (3M)5.07M
Market Cap
HK$36.72B
Enterprise ValueHK$19.66B
Total Cash (Recent Filing)HK$2.54B
Total Debt (Recent Filing)HK$37.07M
Price to Earnings (P/E)29.5
Beta1.25
Next Earnings
Apr 01, 2027Next Dividend Ex-DateN/A
Dividend Yield0.59%
Share Statistics
EPS (TTM)1.55
Shares Outstanding118,995,210
10 Day Avg. Volume5,685,242
30 Day Avg. Volume5,066,315
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.33
Revenue Forecast (FY)HK$2.22B
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low leverage gives JOINN substantial financial flexibility through a range of operating conditions. Limited debt service obligations can preserve funds for research capacity, investment, and working capital while reducing solvency and refinancing pressure.
Strong Profitability ReboundThe current profitability rebound indicates that JOINN can generate substantial earnings from its CRO platform when demand and execution improve. Strong operating and EBITDA margins provide internal funding capacity and could support durable earnings if performance remains consistent.
Positive Cash Generation GrowthPositive operating cash flow and sharply higher free cash flow show that the business is generating funds internally rather than relying solely on external financing. This improves resilience and supports continued investment in capabilities serving pharmaceutical and biotechnology clients.
Bears Say
Weak Cash ConversionCash realization is materially lagging reported earnings, which weakens confidence in the quality and durability of the current profit surge. If this gap persists, JOINN may have less cash available for investment and greater exposure to working-capital demands.
Uneven Revenue TrajectoryThe history of revenue contraction after earlier expansion shows that demand growth has not been consistently sustained. Uneven client activity or project timing could make future performance less predictable and reduce confidence in a smooth multi-quarter growth trajectory.
Volatile ProfitabilityThe sharp change in margins and inconsistent returns on equity indicate that current earnings strength has not yet been proven durable across cycles. Future normalization could materially reduce profitability even if JOINN maintains its underlying CRO operations.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$15.13 and its highest was HK$32.58 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$36.72B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 153 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Oct 28, 2026. The company reported HK$0.283 earnings per share for the quarter, beating the consensus estimate of HK$0.094 by HK$0.189.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Overvalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.138 which represents an annual dividend yield of 0.59%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.283 in its last earnings report, beating expectations of HK$0.094. Following the earnings report the stock price went up 8.889%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.29%
12-Months-Change
Fundamentals
Return on Equity
11.59%
Trailing 12-Months
Asset Growth
27.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
Technical Analysis
Genscript Biotech
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―